Intrahepatic Cholestasis of Pregnancy (ICP): What Every Expectant Mother Should Know

Pregnancy brings all kinds of surprises—some beautiful, others uncomfortable. One condition that can be especially distressing is intrahepatic cholestasis of pregnancy (ICP). Though uncommon, it deserves attention because it can affect both mother and baby.

Intrahepatic cholestasis of pregnancy (ICP) affects approximately 0.3% to 2.9% of pregnancies globally, but prevalence varies widely by geography, ethnicity, and study methodology.

Most large studies and guidelines estimate the prevalence in the United States and other developed countries to be between 0.3% and 0.5%, though rates can be higher in certain populations, such as up to 5.6% among Latina women in the US and 6% in some Chinese cohorts.^[1-6] A recent global meta-analysis found a pooled incidence of 2.9% (95% CI: 2.5–3.3), with higher rates in Asia and lower rates in Oceania and high-income countries.^[7] In South America and Scandinavia, rates may reach 9–15% in some regions.^[1-2][8]

Key risk factors for ICP include advanced maternal age, personal or family history of ICP, certain ethnic backgrounds, hepatitis B or C infection, multiple gestation, and lower socioeconomic status.^[

---

What Is ICP?

• The American Gastroenterological Association (AGA) defines ICP as a liver disorder that usually appears in the second or third trimester of pregnancy, marked by itching (pruritus) and elevated serum bile acids (over 10 µmol/L).
• Most cases begin in the third trimester. Alongside itching, mild to moderate rises in liver enzymes (AST, ALT) can be seen (sometimes 10–20× the upper limit). Total bilirubin is usually less than 6 mg/dL. Elevations in alkaline phosphatase are common but not cannot be used to diagnose this (because the placenta also produces this).
• The classic symptom is itching (can be super intense!)—often on the palms of your hands and soles of your feet—without a rash. Jaundice (yellowing of the skin or eyes) is possible, but not very common.

---

How Is ICP Diagnosed?

• The diagnosis is primarily clinical: persistent itching + elevated serum bile acids (>10 µmol/L).
• If bile acids are normal initially, doctors often retest later, especially after ruling out other causes of itching (like biliary obstruction, viral hepatitis, chronic liver disease, other skin conditions).
• The risk to the baby increases with higher bile acid levels, especially when levels hit ≥100 µmol/L.
• In severe cases, the risk of stillbirth becomes a possibility.

---

What Causes It?

ICP is complex and likely has multiple triggers:

• Genetic factors: Mutations in liver transport proteins, such as MDR3 and BSEP, can reduce the liver’s ability to transport bile acids out of hepatocytes liver cells).
• Hormones of pregnancy: Changes in estrogen and progesterone may worsen bile flow.
• Ethnicity & family history: Some populations (e.g. Scandinavian, South American) have higher rates.
• Environmental/other factors also likely play a role.

---

Why It’s Important (Risks & Outcomes)

For the mother:

• The main issue is discomfort from intense itching, which can be mentally and emotionally exhausting.
• Typically, after delivery, symptoms and lab abnormalities resolve.
• But there is a risk of recurrence in future pregnancies. Some studies also suggest a possible long-term association with liver or metabolic conditions.

For the baby:

• Risks increase with higher bile acid levels (≥100 µmol/L)—these include preterm birth, fetal distress, meconium-stained amniotic fluid, neonatal respiratory distress, and stillbirth.
• Hence, careful monitoring and possibly earlier delivery may be recommended.

---

Treatment: Ursodeoxycholic Acid (UDCA) & Beyond

The main goal of treatment is twofold: relieve the mother’s symptoms and reduce fetal risks.

Ursodeoxycholic Acid (UDCA)

• UDCA is considered the standard first-line therapy. It helps improve bile flow, reduce itching, and normalize liver tests in many women.
• In clinical studies, UDCA has been associated with:
  • Significant reduction or resolution of itching (pruritus)
  • Improvement in liver enzymes and lower bile acid levels
  • Possible reductions in preterm birth, fetal distress, and NICU admissions in some studies (though results vary)

However, when it comes to stillbirth, the evidence is less clear:

• A large individual participant data meta-analysis (over 6,900 women) found no significant difference in stillbirth rates between those treated with UDCA and those not (0.7% vs 0.6%) when considering all studies combined.
• But when focusing only on randomized controlled trials, UDCA showed benefit for a composite outcome (stillbirth + preterm birth), but not a definitive effect on stillbirth alone.
• Some guidelines and reviews still emphasize that while UDCA is effective for the mother’s symptoms, the fetal protections remain debated.

Other therapies (for severe or refractory cases) may include cholestyramine, rifampicin, or S-adenosylmethionine, but their evidence is weaker and often used as adjuncts.

---

Delivery Timing & Monitoring

🕐 When Is Delivery Recommended for Intrahepatic Cholestasis of Pregnancy (ICP)?

Timing of delivery is one of the most important decisions in managing ICP. The goal is to balance the baby’s maturity with the risk of complications, which increases as bile acid levels rise.

According to the Society for Maternal-Fetal Medicine (SMFM) and current obstetric practice, delivery recommendations depend on how high the bile acids are:

Bile Acid Level (µmol/L)	Typical Delivery Timing	Why
Less than 40	Between 36 and 39 weeks (often closer to 38–39 weeks)	Fetal risk is low; delivery can safely occur near full term.
40–99	Around 36–37 weeks	Moderate bile acid levels may raise the chance of fetal distress; many obstetricians plan delivery at 37 weeks.
100 or higher	At or before 36 weeks	The risk of stillbirth increases significantly with very high bile acids; early delivery helps protect the baby.

In practice, many obstetricians choose to deliver at 37 weeks if symptoms are under control and bile acids remain moderate.
The earlier 36-week recommendation is generally reserved for severe ICP, where bile acids reach 100 µmol/L or higher.

This timing strategy—combined with careful fetal monitoring—helps reduce the risk of stillbirth, meconium-stained amniotic fluid, and preterm complications, while giving the baby as much time as possible to mature before birth.

---

What the Evidence Suggests

• The maternal benefits of UDCA are well supported (less itching, better liver tests).
• The protective effect on fetal outcomes, especially stillbirth, is less certain. Large meta-analyses suggest UDCA does not significantly reduce stillbirth rates overall, though some benefit is seen when combining outcomes or focusing on trial data.
• Because stillbirth is a rare event, no single study is likely to offer definitive conclusions—hence the cautious approach in guidelines.
• Ultimately, treatment decisions must balance maternal comfort, severity of disease, fetal risks, and close monitoring.

---

Key Takeaways for Expectant Mothers

1. Don’t ignore persistent itching during pregnancy—especially in palms and soles. Tell your obstetrician.
2. ICP is treatable, especially with UDCA, which often brings relief.
3. But fetal risk is real, especially when bile acids are very high—so follow your doctor’s recommendations for monitoring and delivery timing.
4. After delivery, most women recover, but there is a risk of recurrence in future pregnancies.

---